# Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

> **NCT07681297** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 154 (estimated)

## Conditions studied

- Advanced Solid Tumor Cancer
- Triple-Negative Breast Cancer (TNBC)
- CNS Disease
- Breast Cancer

## Interventions

- **DRUG:** Tislelizumab + Bevacizumab + Capecitabine

## Key facts

- **NCT ID:** NCT07681297
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681297, "Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*